Angiographic result with the use of adenosine before percutaneous coronary intervention in pharmacoinvasive therapy
DOI:
https://doi.org/10.5281/zenodo.10998706Keywords:
No-Reflow Phenomenon, Adenosine, Fibrinolysis, Myocardial InfarctionAbstract
Background: Mexico is the country with the highest mortality from acute myocardial infarction (AMI), which is why guidelines have been established for early reperfusion in which fibrinolysis is the second most accessible method. However, there is a percentage of patients who do not achieve acceptable myocardial perfusion and this is associated with adverse cardiovascular outcomes. Different adenosine schemes have been used as an adjuvant to restore adequate myocardial perfusion.
Objective: To compare the final angiographic flow in patients undergoing pharmacoinvasive percutaneous coronary intervention (PCI) with the use of intracoronary adenosine versus patients without its use.
Material and methods: Single-center, prospective, longitudinal, single-blind study carried out in patients with AMI, thrombolyzed, with reperfusion data, sent to a tertiary care center from March 2022 to June 2023, randomized to receive intracoronary adenosine previous to intervention. Drug-eluting stents were placed in all patients. Initial and final angiographic flow was compared.
Results: 33 patients were included, randomized 1:1 to control and intervention groups. 75.8% of the participants were male. The most frequent artery responsible for the infarction was the anterior descending (63.6%). An average of 350 mcg of intracoronary adenosine was used in the intervention group, and the most frequent complication in both groups was the presence of no-reflow phenomenon.
Conclusions: Due to the small sample size, it is not possible to conclude the usefulness of adenosine for improving final angiographic flow in pharmacoinvasive PCI. More adverse effects were reported in the intervention group, without a significant statistical difference.
Downloads
References
Gómez Fröde, CX, Díaz Echevarría A, Lara Moctezuma L, et. al. Infarto Agudo del Miocardio Como Causa de Muerte. Rev Fac Med (Méx). 2021;64(1):49-59. doi: 10.22201/fm.24484865e.2021.64.1.08.
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
Borrayo-Sánchez G, Alcocer-Gamba MA, Araiza-Garaygordobil D, et al. Guía Práctica interinstitucional para el tratamiento del Infarto Agudo de Miocardio. Gac Med Mex. 2020;156(6). doi: 10.24875/gmm.20000372.
Mora-Solórzano L. Características Clínicas de Pacientes con Infarto Agudo de Miocardio tratados con trombólisis en urgencias. Rev Med Inst Mex Seguro Soc. 2021;58(2). doi: 10.24875/rmimss.m20000006.
Borrayo-Sánchez G, Pérez-Rodríguez G, Martínez-Montáñez O, et al. Protocolo para atención de infarto agudo de miocardio en urgencias: Código Infarto. Rev Med Inst Mex Seguro Soc. 2017;55(2):233-46.
De Marco C, Charron T, Rousseau G. Adenosine in acute myocardial infarction-associated reperfusion injury: Does it still have a role? Front Pharmacol. 2022;13. doi: 10.3389/fphar.2022.856747.
Pérez de Prado A, Fernández-Vázquez F, Carlos Cuellas-Ramón J, et al. Coronariografía: Más Allá de la Anatomía coronaria. Revista Española de Cardiología. 2006;59(6):596 608. doi: 10.1157/13089747.
Rivera-Linares B. M, Bedolla-Barajas M, Morales-Romero J, et. al. Predictores de fenómeno de no reflujo después de intervención coronaria percutánea primaria. Rev Med Inst Mex Seguro Soc. 2014;52(5):522-9.
Refaat H, Tantawy A, Gamal AS, et al. Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Indian Heart J. 2021;73(1):35-43. doi: 10.1016/j.ihj.2020.12.008.
Ruíz-Avalos JA, Bazán-Rodríguez L, Espinoza-Escobar G, et. al. Predictores de fenómeno de no reflujo en infarto agudo del miocardio con elevación del segmento ST. Arch Cardiol Mex. 2022;92(4). doi: 10.24875/acm.21000346.
Sadeghian M, Mousavi SH, Aamaraee Z, et al. Administration of intracoronary adenosine before stenting for the prevention of no-reflow in patients with ST-elevation myocardial infarction. Scand Cardiovasc J. 2022;56(1):23-7. doi: 10.1080/14017431.2022.2035807.
Laborante R, Bianchini E, Restivo A, et al. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):173-82. doi: 10.1093/ehjcvp/pvac069.
Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2011;107(8):1131-5. doi: 10.1016/j.amjcard.2010.12.010.
Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (Amistad-II). Journal of the American College of Cardiology. 2005;45(11):1775-80. doi: 10.1016/j.jacc.2005.02.061.
Beijnink CWH, Woelders ECI, van Geuns RJM. No-reflow after primary PCI: Will distal intracoronary medication do the trick? Cardiovasc Revasc Med. 2023;47:5-7. doi: 10.1016/j.carrev.2022.12.002.
Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. European Heart Journal. 2010;32(7):867-77. doi: 10.1093/eurheartj/ehq492.
Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST-Elevation Myocardial Infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Southampton (UK): NIHR Journals Library; 2016;3(9):1-48. doi: 10.3310/eme03090.
Niu X, Zhang J, Bai M, et al. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with st-elevation myocardial infarction: A network meta-analysis. BMC Cardiovascular Disorders. 2018;18(1). doi: 10.1186/s12872-017-0722-z.
Annibali G, Scrocca I, Aranzulla TC, et al. “No-reflow” phenomenon: A contemporary review. J Clin Med. 2022;11(8):2233. doi :10.3390/jcm11082233.
Caiazzo G, Musci RL, Frediani L, et al. State of the art: No-Reflow phenomenon. Cardiol Clin. 2020;38(4):563-73. doi: 10.1016/j.ccl.2020.07.001.
Kumar D, Ahmed I, Bardooli F, et al. Techniques to treat slow-flow/no-reflow during primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2023;47:1-4. doi: org/10.1016/j.carrev.2022.09.014.
Darwish A, Frere AF, Abdelsamie M, et al. Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study. Ann Saudi Med. 2022;42(2):75-82 doi: 10.5144/0256- 4947.2022.75.
Rezkalla SH, Stankowski RV, Hanna J, et al. Management of no-reflow phenomenon in the catheterization laboratory. JACC: Cardiovascular Interventions. 2017;10(3):215-23. doi: 10.1016/j.jcin.2016.11.059.
Datta G. Intracoronary thrombolysis in no flow after primary percutaneous coronary intervention in acute myocardial infarction. Clinical Cardiology and Cardiovascular Interventions. 2020;3(13):01-5. doi: 10.31579/2641-0419/114
Chen Y, Liu C, Zhou P, et al. Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway. J Recept Signal Transduct Res. 2021;41(6):553-7. doi: 10.1080/10799893.2020.1833921.
Chen WR, Tian F, Chen YD, et al. Effects of liraglutide on no-reflow in patients with Acute St-segment elevation myocardial infarction. International Journal of Cardiology. 2016;208:109-14. doi: 10.1016/j.ijcard.2015.12.009.
Ndrepepa G, Kastrati A. Coronary no-reflow after primary percutaneous coronary intervention—current knowledge on pathophysiology, diagnosis, clinical impact and therapy. Journal of Clinical Medicine. 2023;12(17):5592. doi:10.3390/jcm12175592.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
